IMV News and Press, IMV Inc. From 11/09/20

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV’s executive management team ...

Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...

Results support the interactive mechanism of action of the combination treatment, and the advancement into a potentially pivotal registration trial 86% (6/7) Objective Response Rate (ORR) in patients positive for the PD-L1 biomarker Data to be presented at the SITC Ann...

Are These Biotech Penny Stocks On Your Watch List Right Now? Whether you’re trading penny stocks or blue chips , the goal is the same: make money and repeat. However, with a potentially new President coming into office, there could be a few things to monitor right now. Fi...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that updated clinical data from phase 2 SPiReL study evaluating IMV’s T cell therapy in combin...

IMV to host a combined conference call and webcast on November 12, 2020 at 8:00am ET The webcast will begin with a poster presentation by Dr. Neil Berinstein, Principal Investigator of the SpiReL study, and a discussion about the biomarkers associated with clinical response ...

IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated October 16, 2020, with Piper Sandler & Co. ("Piper Sandler") as agent, pursuant to wh...

Company will discuss the data presented during an online webcast on Thursday, November 12, 2020 at 8.00am ET IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseas...

Consumer Portfolio Services (CPSS) +59% on acquisition proposal by Auto Experience.Eaton Vance (EV) +45% as MS agrees to acquire the company for about $7B.DPW Holdings (DPW) +30% on introducing new energy storage system product line.Alphatec Holdings (ATEC) ...

Selected for additional funding by Canadian Government bringing total support to $10M for clinical development and manufacturing of DPX-COVID-19 Clinical plan updated to run a larger Phase 1/2 study with the goal to expedite later-stage development Collaboration initia...